top of page

New Telehealth Option for Patients and Caregivers Interested in eTNS for Pediatric ADHD








NeuroSigma Announces New Telehealth Option for Patients and Caregivers Interested in eTNS for Pediatric ADHD


LOS ANGELES, March 01, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced a new option for patients and caregivers seeking a telehealth evaluation for the Monarch eTNS System®. NeuroSigma is a Los Angeles-based bioelectronics company commercializing external trigeminal nerve stimulation (eTNS) technology for treating neurological and neuropsychiatric disorders. Its lead product is the Monarch eTNS System, the first-ever FDA cleared non-pharmaceutical treatment for pediatric ADHD.


"NeuroSigma’s mission is to improve the lives of children with ADHD and their families by offering a treatment that is effective, low-risk, and affordable,” said Colin Kealey, M.D., President and CEO of NeuroSigma. “During the COVID-19 pandemic there was a dramatic increase in use of telehealth solutions, and it’s important that patients and families can now speak to a trained provider about the Monarch from the comfort of their own home.”



Please note that an evaluation is not a guarantee of a prescription.


About NeuroSigma

NeuroSigma is a Los Angeles, California-based bioelectronic medical device company developing technologies to transform medical practice and patients' lives. The company is commercializing the Monarch eTNS System, which is the first non-drug treatment for pediatric ADHD cleared by the FDA. Pipeline indications for the Monarch and NeuroSigma’s TNS platform include a wide spectrum of neurological and neuropsychiatric disorders, such as ADHD, drug-resistant epilepsy, and depression. For more information about NeuroSigma, please visit www.neurosigma.com. For more information on the Monarch eTNS System, please visit www.monarch-etns.com.


Contact: Colin Kealey, M.D., President of NeuroSigma at CKealey@neurosigma.com



9 views0 comments

Comments


bottom of page